Biotechnology - Eylea

Filter

Current filters:

Eylea

Popular Filters

1 to 25 of 26 results

Bayer/Regeneron’s Eylea approved in Japan for DME

18-11-2014

German pharma major Bayer’s Japanese subsidiary, Bayer Yakuhin, has received approval from the Ministry…

BayerBiotechnologyEyleaJapanOphthalmicsRegeneronRegulation

Regeneron third-qtr net profit plunges despite strong sales growth

Regeneron third-qtr net profit plunges despite strong sales growth

04-11-2014

US biotech firm Regeneron posted revenue of $725.8 million for the third quarter of 2014, a rise of 22%…

alirocumabBayerBiotechnologydupilumabEyleaFinancialOphthalmicsRegeneronResearchSanofisarilumab

Eylea beats Avastin and Lucentis for visual acuity in DME patients

Eylea beats Avastin and Lucentis for visual acuity in DME patients

19-10-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer saw their shares leap 8.5% to…

AvastinBayerBiotechnologyEyleaGenentechLucentisNovartisOphthalmicsRegeneron PharmaceuticalsResearchRoche

Regeneron gains further FDA indications for Eylea

Regeneron gains further FDA indications for Eylea

07-10-2014

The US Food and Drug Administration has approved biotech firm Regeneron Pharmaceuticals’ Eylea (aflibercept)…

BayerBiotechnologyEyleaOphthalmicsRegeneron PharmaceuticalsRegulationUSA

FDA grants Breakthrough status for Eylea in diabetic retinopathy in patients with DME

FDA grants Breakthrough status for Eylea in diabetic retinopathy in patients with DME

16-09-2014

US biotech firm Regeneron Pharmaceuticals says that the US Food and Drug Administration has granted Eylea…

BayerBiotechnologyEyleaOphthalmicsRegeneron PharmaceuticalsRegulationUSA

Eylea drives Regeneron’s 2nd-qtr to beat expectations

Eylea drives Regeneron’s 2nd-qtr to beat expectations

05-08-2014

USA-based biotech company Regeneron (Nasdaq: REGN) revealed today that total revenues for the second…

BiotechnologyBusiness FinanceEyleaFinancialOphthalmicsRegeneronUSA

Regeneron’s Eylea gains FDA approval for DME

Regeneron’s Eylea gains FDA approval for DME

30-07-2014

The Food and Drug Administration has approved US biotech firm Regeneron Pharmaceuticals’ Eylea (aflibercept)…

BayerBiotechnologyEyleaOphthalmicsRegeneronRegulationUSA

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

11-02-2014

US biotech firm Regeneron Pharmaceuticals reports that its blockbuster ophthalmic drug Eylea (aflibercept)…

BayerBiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronResearchSanofiZaltrap

Positive two-year Ph III VISTA trial of Eylea in DME

Positive two-year Ph III VISTA trial of Eylea in DME

10-02-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer have released positive results…

BayerBiotechnologyEyleaOphthalmicsRegeneronResearch

Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD

14-01-2014

US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…

BayerBiotechnologyEyleaLicensingOphthalmicsRegeneronResearch

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan

23-11-2013

There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Regeneron 3rd-qtr beats expectations, as total revenues leap 40%

Regeneron 3rd-qtr beats expectations, as total revenues leap 40%

06-11-2013

US biotech firm Regeneron Pharmaceuticals has posted financial and operating results for the third quarter…

BayerBiotechnologyEyleaFinancialOphthalmicsRegeneron

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Regeneron revenues leap on Eylea progress

06-08-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares fall 4% to $260 in pre-market…

BayerBiotechnologyEyleaFinancialRegeneron

Eylea meets primary endpoint in Ph III DME study

06-08-2013

German pharma major Bayer (BAYN: DE) revealed this morning (August 6) that, in the Phase III VIVID-DME…

BayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronResearch

Positive Ph III results for Regeneron/Bayer's Eylea in mCNV

06-06-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) and partner Germany's Bayer (BAYN: DE) have…

BayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronResearch

Regeneron acquires rights to two ophthalmology programs from Sanofi

03-05-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) has expanded its ophthalmology portfolio by…

BiotechnologyEyleaFinancialLicensingOphthalmicsPharmaceuticalRegeneronSanofi

Regeneron posts strong growth for 2012, beating analysts' estimates

15-02-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) yesterday announced that total revenues were…

BiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronZaltrap

Recent Eylea growth in USA appears to be coming from expanded uptake among prescribers

07-01-2013

After one year on the market, 86% of US retinal specialists have prescribed Regeneron's (Nasdaq: REGN)…

BayerBiotechnologyEyleaMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneron

Bayer files for Japanese approval of Eylea for macular edema following CRVO

07-01-2013

German drug major Bayer(BAYN: DE) says its subsidiary Bayer Yakuhin has applied to the Japanese Ministry…

afliberceptAsia-PacificBayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronRegulationSanten Pharmaceuticals

1 to 25 of 26 results

COMPANY SPOTLIGHT

Menarini

Back to top